ArticleESMO real world data and digital oncology2023
ESMO Guidance for Reporting Oncology real-World evidence (GROW).
Article in ESMO real world data and digital oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Real-world survival benefit of adding durvalumab to chemotherapy in cholangiocarcinoma: a retrospective cohort analysis from a German Comprehensive Cancer Centre.ESMO real world data and digital oncology · 2026Article
- From rejection to formative development: recalibrating decisions for under-resourced authors.ESMO real world data and digital oncology · 2026Review
- Real-world outcomes of chemoimmunotherapy in advanced biliary tract cancer: a multicenter study with a propensity-matched historical cohort.ESMO real world data and digital oncology · 2026Article
- Primary care physician documentation in oncology electronic health records: prognostic marker or immortal-time bias?ESMO real world data and digital oncology · 2026Article
- Development and evaluation of a large language model-based, retrieval-augmented generation application for query response in early oncology clinical trials.ESMO real world data and digital oncology · 2026Article
- Article
- Article
- The role of socioeconomic position in use of systemic anticancer therapy.ESMO real world data and digital oncology · 2026Article
- Real-world data on oncology in Morocco: a narrative review of four decades of national evidence.Journal of cancer research and clinical oncology · 2026Review
- Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer.British journal of cancer · 2026Article
- Fully Automated Abstraction of Longitudinal Breast Oncology Records with Off-The-Shelf Large Language Models.medRxiv : the preprint server for health sciences · 2026Article
- A Standardized Guideline for Assessing Extracted Electronic Health Records Cohorts: A Scoping Review.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
•Real-world evidence in oncology is evolving rapidly with many particularities.•This guidance provides key recommendations for reporting real-world evidence studies in oncology.•Recommendations are based on a review of current evidence and the authors' collective expert opinion.•Authors are a multidisciplinary group of experts from different institutions and countries.•Guidance is provided for full article development, including title, introduction, methods, results, discussion, conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.